INmune Bio FCF Margin

What does INmune Bio do? INmune Bio, Inc. is an emerging biotechnology company specializing in the development of immunotherapies for previously incurable diseases. The company was founded in 2015 and is headquartered in La Jolla, California. The company was founded by Dr. RJ Tesi, who was previously a senior scientist at another biotech firm. Dr. Tesi and his research team were frustrated with the disappointing results of existing treatments for a variety of diseases, including cancer, Alzheimer's, and Parkinson's. They decided to explore a new type of immunotherapy that would better address the complexities of the immune system. After years of research and development, INmune Bio has successfully developed several drug candidates, some of which are already being tested in clinical trials. INmune Bio's business model focuses on the invention of safe, affordable, and easy-to-use immunotherapies based on NK and T cells. Their goal is to combat chronic inflammation, glial stress, and neurodegenerative diseases through the use of drug candidates. The company has established strong partnerships with academic and clinical partners both in the US and internationally. INmune Bio is expected to focus on the further development and approval of several groundbreaking therapy options in the coming years. INmune Bio is divided into two divisions: INKmune and XPro1595. The INKmune technology platform is focused on strengthening a key component of the immune system, namely natural killer cells (NK cells). NK cells play an important role in the destruction of abnormal cells such as cancer cells. The INKmune technology aims to support the immune system through a combination of drugs and host metabolism changes, not only applying to cancer cells but also to other diseases such as Alzheimer's. XPro1595 is a drug candidate that is able to stop the inflammatory process by specifically inhibiting the activity of microglia cells in the brain. These cells are activated in many diseases, such as Alzheimer's, autoimmune diseases, or traumatic brain injuries. XPro1595 is intended to slow down the progressive course of these diseases by inhibiting harmful inflammation. INmune Bio currently has one drug candidate in Phase 1b clinical trials, INKmune. INKmune is a novel drug that aims to support the immune system by activating natural killer cells (NK cells). It has been developed to induce a comprehensive immune response to tumors of any kind. XPro1595 has also been developed to be used in various diseases, including Alzheimer's and Parkinson's. The drug is currently in Phase 2 clinical trials. In conclusion, INmune Bio is a biotechnology company specializing in immunotherapies. Their two main divisions, INKmune and XPro1595, aim to modulate the immune system and combat inflammation to treat various diseases. INmune Bio already has drug candidates in clinical development and works closely with academic and clinical partners. The company is expected to expand its portfolio of innovative therapy options and seek approval for additional drugs in the coming years. INmune Bio is one of the most popular companies on Eulerpool.